Based on the validation of the prognostic value of DLX1 in different subgroups, we further determined the prognostic value of DLX1 in different clinical subgroups, namely pathological stage, tumor lymph node metastasis (TNM) stage, gender, age, race, smoking status, and smoking age. Here, DLX1 is linked to neoplasm.